Turn Therapeutics (NASDAQ:TTRX) Issues Earnings Results

Turn Therapeutics (NASDAQ:TTRX) released its quarterly earnings results on Monday. The company reported ($0.03) earnings per share (EPS) for the quarter, FiscalAI reports.

Turn Therapeutics Stock Up 2.6%

Turn Therapeutics stock opened at $3.98 on Wednesday. Turn Therapeutics has a twelve month low of $2.57 and a twelve month high of $26.50. The stock’s 50 day moving average is $3.49. The firm has a market cap of $118.56 million and a PE ratio of -24.88.

Institutional Trading of Turn Therapeutics

Several hedge funds have recently modified their holdings of the business. Hodges Capital Management Inc. acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $39,000. LPL Financial LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $51,000. Tamar Securities LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $59,000. Composition Wealth LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $63,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Turn Therapeutics in the 4th quarter valued at approximately $68,000.

Wall Street Analyst Weigh In

Separately, D. Boral Capital restated a “buy” rating and set a $8.00 price target on shares of Turn Therapeutics in a research note on Tuesday, March 24th. One analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.00.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers. This innovation reduces the quantity of required API inclusion by improving its bioavailability. Reduced API load reduces the likelihood of adverse events.